Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Naunyn Schmiedebergs Arch Pharmacol. 2011 Dec;384(6):565-81. doi: 10.1007/s00210-011-0686-y. Epub 2011 Sep 25.
Pharmacologic antagonism of cannabinoid 1 receptors (CB1 receptors) in the central nervous system (CNS) suppresses food intake, promotes weight loss, and improves the metabolic profile. Since the CB1 receptor is expressed both in the CNS and in peripheral tissues, therapeutic value may be gained with CB1 receptor inverse agonists acting on receptors in both domains. The present report examines the metabolic and CNS actions of a novel CB1 receptor inverse agonist, compound 64, a 1,5,6-trisubstituted pyrazolopyrimidinone. Compound 64 showed similar or superior binding affinity, in vitro potency, and pharmacokinetic profile compared to rimonabant. Both compounds improved the metabolic profile in diet-induced obese (DIO) rats and obese cynomolgus monkeys. Weight loss tended to be greater in compound 64-treated DIO rats compared to pair-fed counterparts, suggesting that compound 64 may have metabolic effects beyond those elicited by weight loss alone. In the CNS, reversal of agonist-induced hypothermia and hypolocomotion indicated that compound 64 possessed an antagonist activity in vivo. Dosed alone, compound 64 suppressed extinction of conditioned freezing (10 mg/kg) and rapid eye movement (REM) sleep (30 mg/kg), consistent with previous reports for rimonabant, although for REM sleep, compound 64 was greater than threefold less potent than for metabolic effects. Together, these data suggested that (1) impairment of extinction learning and REM sleep suppression are classic, centrally mediated responses to CB1 receptor inverse agonists, and (2) some separation may be achievable between central and peripheral effects with brain-penetrating CB1 receptor inverse agonists while maintaining metabolic efficacy. Furthermore, chronic treatment with compound 64 contributes to evidence that peripheral CB1 receptor blockade may yield beneficial outcomes that exceed those elicited by weight loss alone.
在中枢神经系统 (CNS) 中,大麻素 1 型受体 (CB1 受体) 的药物拮抗作用可抑制食欲、促进体重减轻并改善代谢特征。由于 CB1 受体在中枢神经系统和外周组织中均有表达,因此具有双重作用域的 CB1 受体反向激动剂可能具有治疗价值。本报告研究了一种新型 CB1 受体反向激动剂化合物 64 的代谢和 CNS 作用,化合物 64 是一种 1,5,6-三取代的吡唑并嘧啶酮。与利莫那班相比,化合物 64 具有相似或更高的体外结合亲和力、效力和药代动力学特征。这两种化合物均改善了饮食诱导肥胖 (DIO) 大鼠和肥胖食蟹猴的代谢特征。与配对喂养的 DIO 大鼠相比,用化合物 64 治疗的大鼠体重减轻趋势更大,这表明化合物 64 可能具有除体重减轻以外的代谢作用。在 CNS 中,激动剂引起的体温降低和运动减少的逆转表明化合物 64 在体内具有拮抗活性。单独给药时,化合物 64 可抑制条件性冻结(10mg/kg)和快速眼动(REM)睡眠的消退(30mg/kg),这与利莫那班的先前报道一致,尽管对于 REM 睡眠,化合物 64 的效力比代谢作用低三倍多。总的来说,这些数据表明:(1)消退学习的损伤和 REM 睡眠的抑制是 CB1 受体反向激动剂的经典、中枢介导的反应,(2)具有穿透血脑屏障的 CB1 受体反向激动剂可能在保持代谢疗效的同时,实现中枢和外周作用之间的某种分离。此外,用化合物 64 进行慢性治疗为外周 CB1 受体阻断可能产生超过单纯体重减轻的有益结果提供了证据。